Eli Lilly, the first to announce insulin price cuts this month, will slash the drugmaker's most commonly prescribed insulin Humalog to $66.40 per vial, down from $274.70. It will implement price ...

Sanofi is cutting the list price of Lantus, its most widely prescribed insulin in the US, by 78% and establishing a $35 monthly cap for those with private insurance, the company announced Thursday.

Sanofi SNY announced up to a 78% cut in the list price of its most popular insulin, Lantus, following the likes of rival Novo Nordisk NVO and Eli Lilly LLY.Similar to Lilly, Sanofi also said it is ...

Sanofi's Lantus insulin injection will see its price cut by 78%, the company announced Thursday. The out-of-pocket cost for all patients will be $35 for a monthly supply.

Sanofi has followed in the footsteps of its rivals in the US insulin market with a 78% price cut for its most widely-used Lantus product starting next January.

Along with cutting down the price of Lantus, a long-acting injection insulin, the company said it would be reducing the cost of its fast-acting insulin product Apidra by 70 percent.

The current list price for a 10-milliliter vial of the fast-acting, mealtime insulin Humalog is currently $274.70 and will fall to $66.40, while the same amount of Humulin will drop from $148.70 ...

Over that period, Sanofi tripled the price of its Lantus insulin to about $275 per vial. A 2018 study estimated it costs roughly $2 to $4 to produce a vial of analog insulin, the type used by most ...

Lantus 100iu - 3 ml Injection (Insulin Glargine) drug information. Find its price or cost, dose, when to use, how to use, side effects, adverse effects, substitutes . It is manufactured by Sanofi ...